Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages

  Freed, Daniel C ^a   Tang, Qi ^b,c   Tang, Aimin ^a   Li, Fengsheng ^a   He, Xi ^a   Huang, Zhao ^b   Meng, Weixu ^b   Xia, Lin ^b   Finnefrock, Adam C ^a   Durr, Eberhard ^a   Espeseth, Amy S ^a   Casimiro, Danilo R ^a   Zhang, Ningyan ^b   Shiver, John W ^a,d   Wang, Dai ^a   An, Zhiqiang ^b   Fu, Tong Ming ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c NANJING MEDICAL UNIVERSITY   (China)

^d SANOFI PASTEUR   (France)

Author keywords

Antiviral antibody; Monoclonal antibody

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN H; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ARTICLE; CELL LINEAGE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GENETIC ANALYSIS; HUMAN CYTOMEGALOVIRUS; LIGHT CHAIN; NONHUMAN; PHYLOGENETIC TREE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RABBIT; SEQUENCE HOMOLOGY; SOMATIC MUTATION; VACCINATION; VIRAL TROPISM; VIRUS ENTRY; VIRUS NEUTRALIZATION;

EID: 84890850632     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316517110     Document Type: Article

References (79)

1. Beam E, Razonable RR (2012) Cytomegalovirus in solid organ transplantation: Epidemiology, prevention, and treatment. Curr Infect Dis Rep 14(6):633-641.
2. Boeckh M, Ljungman P (2009) How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113(23):5711-5719.
3. Fishman JA (2007) Infection in solid-Organ transplant recipients. N Engl J Med 357(25): 2601-2614.
4. Kotton CN (2010) Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 6(12):711-721.
5. Opelz G, Dohler B, Ruhenstroth A (2004) Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 4(6):928-936.
6. Limaye AP, et al. (2006) Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12):1645-1652.
7. Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34(8):1094-1097.
8. Arvin AM, et al. (2004) Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin Infect Dis 39(2):233-239.
9. Kenneson A, Cannon MJ (2007) Review and meta-Analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17(4):253-276.
10. Revello MG, Gerna G (2002) Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15(4): 680-715.
11. Dollard SC, Grosse SD, Ross DS (2007) New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17(5):355-363.
12. Fowler KB, Stagno S, Pass RF (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289(8):1008-1011.
13. Fowler KB, et al. (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326(10):663-667.
14. Lilleri D, et al. (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8(3):e59863.
15. Lilleri D, et al. (2007) Development of human cytomegalovirus-Specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195(7):1062-1070.
16. Lilleri D, Fornara C, Revello MG, Gerna G (2008) Human cytomegalovirus-Specific memory CD8+ and CD4+ T cell differentiation after primary infection. J Infect Dis 198(4):536-543.
17. Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353(13):1350-1362.
18. Visentin S, et al. (2012) Early primary cytomegalovirus infection in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 55(4):497-503.
19. Institute of Medicine (2000) Vaccines for the 21st Century: A Tool for Decisionmaking, eds Stratton KR, Durch JS, Lawrence RS (National Academies Press, Washington, DC).
20. Adler SP (2008) Human CMV vaccine trials: What if CMV caused a rash J Clin Virol 41(3):231-236.
21. Sung H, Schleiss MR (2010) Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 9(11):1303-1314.
22. Murphy E, et al. (2003) Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci USA 100(25):14976-14981.
23. Chee MS, et al. (1990) Analysis of the protein-Coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125-169.
24. Dolan A, et al. (2004) Genetic content of wild-Type human cytomegalovirus. J Gen Virol 85(Pt 5):1301-1312.
25. Stern-Ginossar N, et al. (2012) Decoding human cytomegalovirus. Science 338(6110): 1088-1093.
26. Gatherer D, et al. (2011) High-Resolution human cytomegalovirus transcriptome. Proc Natl Acad Sci USA 108(49):19755-19760.
27. Schleiss MR, Heineman TC (2005) Progress toward an elusive goal: Current status of cytomegalovirus vaccines. Expert Rev Vaccines 4(3):381-406.
28. Waldman WJ, Sneddon JM, Stephens RE, Roberts WH (1989) Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells. J Med Virol 28(4):223-230.
29. Patrone M, et al. (2005) Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 79(13): 8361-8373.
30. Kahl M, Siegel-Axel D, Stenglein S, Jahn G, Sinzger C (2000) Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol 74(16): 7628-7635.
31. Jarvis MA, et al. (1999) Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol 73(6): 4552-4560.
32. Gerna G, et al. (2000) Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74(12):5629-5638.
33. Gerna G, Percivalle E, Sarasini A, Revello MG (2002) Human cytomegalovirus and human umbilical vein endothelial cells: Restriction of primary isolation to blood samples and susceptibilities of clinical isolates from other sources to adaptation. J Clin Microbiol 40(1):233-238.
34. Sinzger C, et al. (1995) Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol 76(Pt 4):741-750.
35. Sinzger C, Jahn G (1996) Human cytomegalovirus cell tropism and pathogenesis. Intervirology 39(5-6):302-319.
36. Sinzger C, Plachter B, Stenglein S, Jahn G (1993) Immunohistochemical detection of viral antigens in smooth muscle, stromal, and epithelial cells from acute human cytomegalovirus gastritis. J Infect Dis 167(6):1427-1432.
37. Britt W (2007) Virus entry into host, establishment of infection, spread in host, mechanisms of tissue damage. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, eds Arvin A, et al. (Cambridge Univ Press, Cambridge).
38. Roberts WH, Sneddon JM, Waldman J, Stephens RE (1989) Cytomegalovirus infection of gastrointestinal endothelium demonstrated by simultaneous nucleic acid hybridization and immunohistochemistry. Arch Pathol Lab Med 113(5):461-464.
39. Mocarski ES, Shenk T, Pass RF (2007) Cytomegaloviruses. Fields Virology, eds Knipes DM, Howley PM (Lippincott Williams & Wilkins, Philadelphia), pp 2701-2772.
40. Cha TA, et al. (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70(1):78-83.
41. Dargan DJ, et al. (2010) Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 91(Pt 6):1535-1546.
42. Wang D, Shenk T (2005) Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79(16):10330-10338.
43. Hahn G, et al. (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78(18): 10023-10033.
44. Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102(50):18153-18158.
45. Revello MG, Gerna G (2010) Human cytomegalovirus tropism for endothelial/epithelial cells: Scientific background and clinical implications. Rev Med Virol 20(3): 136-155.
46. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 17(3): 200-206.
47. Griffiths PD, et al. (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-Controlled trial. Lancet 377(9773):1256-1263.
48. Pass RF, et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360(12):1191-1199.
49. Plotkin SA, et al. (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58(11):1176-1178.
50. Cui X, Meza BP, Adler SP, McVoy MA (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26(45):5760-5766.
51. Wang D, et al. (2011) Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29(48):9075-9080.
52. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-Cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86(13):7444-7447.
53. Fu TM, et al. (2012) Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30(52):7469-7474.
54. Macagno A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84(2):1005-1013.
55. Tang A, et al. (2011) A novel high-Throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 29(46):8350-8356.
56. Wang D, Yu QC, Schröer J, Murphy E, Shenk T (2007) Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci USA 104(50):20037-20042.
57. Strohl WR (2009) Therapeutic Monoclonal Antibodies: From Bench to Clinic (Wiley, New York), 1st Ed.
58. Scheid JF, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-Infected individuals. Nature 458(7238):636-640.
59. Breden F, et al. (2011) Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 6(3):e16857.
60. Nadel B, Feeney AJ (1997) Nucleotide deletion and P addition in V(D)J recombination: A determinant role of the coding-End sequence. Mol Cell Biol 17(7):3768-3778.
61. Wu X, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049):1593-1602.
62. Varnum SM, et al. (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome. J Virol 78(20):10960-10966.
63. Compton T (2004) Receptors and immune sensors: The complex entry path of human cytomegalovirus. Trends Cell Biol 14(1):5-8.
64. Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC (2010) A human cytomegalovirus gO-Null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 84(5): 2585-2596.
65. Cannon MJ, et al. (2012) Awareness of and behaviors related to child-To-Mother transmission of cytomegalovirus. Prev Med 54(5):351-357.
66. Gerna G, et al. (2008) Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89(Pt 4):853-865.
67. Waldman WJ, Knight DA, Huang EH, Sedmak DD (1995) Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: An in vitro model. J Infect Dis 171(2):263-272.
68. Jarvis MA, Nelson JA (2007) Human cytomegalovirus tropism for endothelial cells: Not all endothelial cells are created equal. J Virol 81(5):2095-2101.
69. Arai Y, et al. (2012) Effects of intrapulmonary viral tropism and cytokine expression on the histological patterns of cytomegalovirus pneumonia. Pathol Int 62(9):628-639.
70. Rummelt V, et al. (1994) Triple retinal infection with human immunodeficiency virus type 1, cytomegalovirus, and herpes simplex virus typee Light and electron microscopy, immunohistochemistry, and in situ hybridization. Ophthalmology 101(2): 270-279.
71. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A (2008) CMV-Hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-Analysis. Clin Transplant 22(1):89-97.
72. Baldanti F, et al. (2006) Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. Arch Virol 151(6):1225-1233.
73. Spaete RR, et al. (1990) Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 64(6):2922-2931.
74. Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.
75. Yu Y, et al. (2010) A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One 5(2):e9072.
76. High K, Meng Y, Washabaugh MW, Zhao Q (2005) Determination of picomolar equilibrium dissociation constants in solution by enzyme-Linked immunosorbent assay with fluorescence detection. Anal Biochem 347(1):159-161.
77. Meng Y, High K, Antonello J, Washabaugh MW, Zhao Q (2005) Enhanced sensitivity and precision in an enzyme-Linked immunosorbent assay with fluorogenic substrates compared with commonly used chromogenic substrates. Anal Biochem 345(2): 227-236.
78. Rader C, et al. (2000) The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 275(18):13668-13676.
79. Larkin MA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23(21): 2947-2948.